Skip to main content
    B

    Bristol-Myers Squibb Company (BMY)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $62.94
    -0.49 (-0.77%)

    Market Cap: $129.66B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Bristol-Myers Squibb Company (BMY) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Bristol-Myers Squibb Company (BMY) trades at 10.1x trailing earnings and 2.6x sales. Its P/E of 10.1x is above its 5-year median of 9.2x. Its forward P/E is 9.6x. The median P/E across 9 similar companies is 21.4x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 5.2% higher over the next year. PEG is left out because the growth rate behind it, P/E divided by PEG, is under 2% a year.

    MultipleValue
    P/E (trailing)10.1x
    Forward P/E9.6x
    Price to sales2.6x
    Price to book5.5x
    EV/EBITDA11.5x
    Price to FCF13.9x
    EV/FCF17.4x
    PEGN/A
    FCF yield7.2%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/E is 1.0% below 10.2x, its P/S is 21.2% below 3.3x and its P/B is 5.8% above 5.2x.

    MultipleCurrent5-year median10-year median
    P/E10.1x9.2x10.2x
    P/S2.6x2.5x3.3x
    P/B5.5x5.1x5.2x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/E ranged from 6.9x in 2023 to 49.6x in 2024.

    Year endPriceP/EP/SP/B
    2025$53.948.8x2.3x6.0x
    2024$56.5649.6x2.4x7.1x
    2023$51.316.9x2.4x3.5x
    2022$71.959.3x3.3x4.9x
    2021$62.358.3x3.0x3.8x
    2020$62.039.6x3.7x3.7x
    2019$64.1913.7x4.2x2.4x
    2018$51.9813.1x3.8x6.1x
    2017$61.2820.4x4.8x8.6x
    2016$58.4420.7x5.0x6.1x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About BMY

    What is BMY's forward P/E ratio?

    Bristol-Myers Squibb Company has a forward P/E ratio of 9.6x.

    Is BMY stock overvalued?

    GNG's valuation label for BMY is Fairly valued. Its P/E of 10.1x compares with a median of 21.4x across 9 similar companies.

    What is BMY's price to sales ratio?

    Bristol-Myers Squibb Company has a price to sales ratio of 2.6x.

    What is Bristol-Myers Squibb Company's average P/E ratio over 5 years?

    Bristol-Myers Squibb Company's median P/E over the last 5 years is 9.2x, from 60 month-end values through Oct 2026.